Free public records show J Molner in 1 of the markets we cover. It is not a key player in our research.
From public registers, not from Acuitas research, with a citation under every number. Each card opens the full list at its source.
14 approvals with a product on the US market
Source: Drugs@FDA, Approvals (NDA, ANDA, BLA) held, with a product sold now; newest shown. Retrieved 13 Nov 2026.
Markets we cover where free public records show J Molner: trials they lead, US approvals or WHO prequalification. Each opens the market's report, with the record counts and their sources.
The topics of the markets J Molner is in.
Stories on the topics J Molner works in.
WHO says only about half of patients in developed countries take long-term medicines as prescribed. Patient…
Read
Every vaccine, antibody and cell therapy must be tested for sterility, purity and viruses before it reaches…
Read
The first CAR-T cell therapy was approved in the US in August 2017. These living drugs can work when other…
Read